A Phase 1 Oral Mass Balance and Combined Intravenous 14 C Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans

Key Points

• This research aims to characterize the absorption, metabolism, excretion, and pharmacokinetics of the antitumor drug E7386 in humans.
• Oral and intravenous (IV) administration of E7386 was tested in healthy participants.
• Phase 1 study design focusing on mass balance and metabolism tracking through microtracers.
• Assessment of tolerability and adverse events following drug administration.
• E7386-related material is primarily excreted in feces post oral administration.
• IV and oral dosing of E7386 was well-tolerated with manageable adverse events.